Skip to content
Open access · CC-BY via OpenAlex

Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease

Sweta Ghosh, Rajbir Singh, Zachary Matthew Vanwinkle, Craig James McClain, Vatsalya Vatsalya, Bodduluri Haribabu, Praveen Kumar Vemula, Venkatakrishna Rao Jala

Frontiers in Pharmacology · 2026 · ▲ 4 citations

Abstract

Background and Aims Excessive alcohol consumption poses a significant global health concern, ranking as the world’s third-largest risk factor for diseases and disabilities, contributing to 5.9% of all deaths worldwide. Among various disorders linked to alcohol misuse, alcohol-associated liver disease (ALD) is the most prominent. ALD patients often exhibit increased intestinal permeability, systemic inflammation, gut dysbiosis, and hepatic steatosis. No FDA-approved therapies are available to treat ALD or to resolve the pathological domains of alcohol-induced gut barrier dysfunction, inflammation, and steatosis. The goal of this study is to investigate the potential therapeutic role of the microbial metabolite Urolithin A’ (UroA), in alleviating ALD. Methods Caco-2 (monolayer colon epithelial) cells and AML12 (hepatocytes) cells were used to test the protective activities of UroA against EtOH-induced gut barrier dysfunction and lipid accumulation in vitro. Preclinical ALD mouse models were used to test the therapeutic potential of UroA against EtOH exposure. Additionally, we generated cell-specific deletion mice with aryl hydrocarbon receptor (AHR) deletion to define the role of intestinal epithelial cell AHR in UroA-mediated protective activities against ALD. Results The results presented here demonstrate the efficacy of UroA as a potential therapeutic agent to protect against EtOH-induced disruption of tight junction proteins, inflammation, and lipogenesis both in vitro and in vivo models. Conclusion Our findings suggest that the simultaneous targeting of gut barrier dysfunction, inflammation, and hepatic steatosis by treatment with UroA may offer new possibilities for combating ALD. Moreover, our results suggest that UroA-mediated protective activities against EtOH-induced gut barrier dysfunction and inflammation in ALD are dependent on intestinal epithelial cell-AHR.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3389/fphar.2025.1706111
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Ghosh, S., Singh, R., Vanwinkle, Z.M., McClain, C.J., Vatsalya, V., Haribabu, B., Vemula, P.K., &amp; Jala, V.R. (2026). Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease. <em>Frontiers in Pharmacology</em>. https://doi.org/10.3389/fphar.2025.1706111
Vancouver
Ghosh S, Singh R, Vanwinkle ZM, McClain CJ, Vatsalya V, Haribabu B, et al. Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease. Frontiers in Pharmacology. 2026. doi:10.3389/fphar.2025.1706111.
BibTeX
@article{sweta2026Urolit, title = {Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease}, author = {Sweta Ghosh and Rajbir Singh and Zachary Matthew Vanwinkle and Craig James McClain and Vatsalya Vatsalya and Bodduluri Haribabu and Praveen Kumar Vemula and Venkatakrishna Rao Jala}, journal = {Frontiers in Pharmacology}, year = {2026}, doi = {10.3389/fphar.2025.1706111}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings